IN THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1-22 (Cancelled)

23. (New) A method of enhancing an immune response in a patient having soluble cytokine receptor molecules in the blood which inhibit the immune response, the method comprising:

(a) obtaining whole blood from the patient;

(b) separating plasma from the blood;

(c) contacting the plasma with at least one cytokine receptor inhibitor selected from the group consisting of antibodies or antibody fragments binding to soluble cytokine receptor molecules, and cytokine molecules and epitopes thereof binding to soluble cytokine receptor molecules;

(d) removing soluble cytokine receptor molecules bound to the cytokine receptor inhibitor from the plasma; and

(e) returning the plasma from which the soluble cytokine receptor molecules have been removed to the patient.

24. (New) The method of claim 23, wherein the cytokine receptor inhibitor is immobilized in a solid support or membrane.

25. (New) The method of claim 23, wherein the antibodies are recombinant.

26. (New) The method of claim 23, wherein the antibodies are in a mixture of antibodies immunoreactive with the soluble cytokine receptor molecules.

27. (New) The method of claim 23, wherein the patient is human.

28. (New) The method of claim 23, wherein the soluble cytokine receptor is selected from the group consisting of soluble receptors for tumor necrosis factors alpha and beta.

29. (New) The method of claim 23, wherein the soluble cytokine receptor is selected from the group consisting of TNF receptor, interleukin-1 receptor, and interleukin-6 receptor.

30. (New) The method of claim 23, wherein the soluble cytokine receptor molecule is a soluble interleukin-1 receptor or a soluble interleukin-6 receptor.

31. (New) The method of claim 23, wherein the soluble cytokine receptor molecule is a TNF receptor.

32. (New) The method of claim 23, wherein the antibodies or antibody fragments are monoclonal.

33. (New) The method of claim 23, wherein the monoclonal antibodies or antibody fragments are recombinant.

34. (New) The method of claim 23, wherein the plasma is contacted with antibodies or antibody fragments.

35. (New) The method of claim 23, wherein the plasma is contacted with polyclonal antibodies or antibody fragments.

36. (New) The method of claim 23, wherein the plasma is contacted with monoclonal antibodies or antibody fragments.

37. (New) The method of claim 23, wherein the plasma is contacted with the cytokines or cytokine epitopes.

38. (New) The method of claim 36, wherein the monoclonal antibodies or antibody fragments are recombinant.

39. (New) The method of claim 23, wherein the blood is separated into plasma by filtration.

40. (New) The method of claim 39, wherein the filtration is ultrafiltration.

41. (New) The method of claim 23, wherein steps (a)-(e) are repeated.

SUPPORT FOR THE AMENDMENTS

Set forth below is a claim chart showing the written description for claims 23-41 of the present application in the specification of that application.

Claim	Specification
23. A method of enhancing an immune response in a patient having soluble cytokine receptor molecules in the blood which inhibit the immune response, the method comprising:	Page 1, lines 6-7
(a) obtaining whole blood from the patient;	Page 18, lines 4-8
(b) separating plasma from the blood;	Page 18, lines 6-8.
(c) contacting the plasma with at least one cytokine receptor inhibitor selected from the group consisting of antibodies or antibody fragments binding to soluble cytokine receptor molecules, and cytokine molecules and epitopes thereof binding to soluble cytokine receptor molecules;	Page 6, lines 13-20; page 18, lines 8-11
(d) removing soluble cytokine receptor molecules bound to the cytokine receptor inhibitor from the plasma; and	Page 6, lines 13-20; page 18, lines 8-18
(e) returning the plasma from which the soluble cytokine receptor molecules have been removed to the patient.	Page 18, lines 12-15
24. The method of claim 23, wherein the cytokine receptor inhibitor is immobilized in a solid support or membrane.	Page 6, line 15 and page 9, line 4
25. The method of claim 23, wherein the antibodies are recombinant.	Page 6, lines 18-20
26. The method of claim 23, wherein the antibodies are in a mixture of antibodies immunoreactive with the soluble cytokine receptor molecules.	Page 6, lines 14-18

27. The method of claim 23, wherein the patient is human.	Page 6, line 26
28. The method of claim 23, wherein the soluble cytokine receptor is selected from the group consisting of soluble receptors for tumor necrosis factors alpha and beta.	Page 3, lines 14-17
29. The method of claim 23, wherein the soluble cytokine receptor is selected from the group consisting of TNF receptor, interleukin-1 receptor, and interleukin-6 receptor.	Page 6, lines 1-7 and page 9, line 19-20
30. The method of claim 23, wherein the soluble cytokine receptor molecule is a soluble interleukin-1 receptor or a soluble interleukin-6 receptor.	Page 6, lines 1-7
31. The method of claim 23, wherein the soluble cytokine receptor molecule is a TNF receptor.	Page 9, lines 19-20
32. The method of claim 23, wherein the antibodies or antibody fragments are monoclonal.	Page 6, line 27
33. The method of claim 23, wherein the monoclonal antibodies or antibody fragments are recombinant.	Page 6, lines 18-20
34. The method of claim 23, wherein the plasma is contacted with antibodies or antibody fragments.	Page 6, lines 18-20
35. The method of claim 23, wherein the plasma is contacted with polyclonal antibodies or antibody fragments.	Page 6, line 27
36. The method of claim 23, wherein the plasma is contacted with monoclonal antibodies or antibody fragments.	Page 6, line 27
37. The method of claim 23, wherein the plasma is contacted with the	Page 6, lines 13-14

cytokines or cytokine epitopes.

38. The method of claim 36, wherein the monoclonal antibodies or antibody fragments are recombinant.	Page 6, lines 18-20
39. The method of claim 23, wherein the blood is separated into plasma by filtration.	Page 6, line 15; page 12, line 12 to page 13, line 2; and page 18, lines 4-8
40. The method of claim 39, wherein the filtration is ultrafiltration.	Page 12, line 12 to page 13, line 2; and page 18, lines 4-8
41. The method of claim 23, wherein steps (a)-(e) are repeated.	Page 18, lines 21-24